These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 16387078)

  • 1. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
    Chen JH; Mao YY; He Q; Wu JY; Lv R
    Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
    Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
    Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients.
    Helantera I; Koskinen P; Tornroth T; Loginov R; Gronhagen-Riska C; Lautenschlager I
    Transplantation; 2003 Jun; 75(11):1858-64. PubMed ID: 12811246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
    Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
    Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
    Stratta RJ; Alloway RR; Lo A; Hodge EE;
    Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G; Daniel V; Naujokat C; Döhler B
    Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
    Potena L; Holweg CT; Chin C; Luikart H; Weisshaar D; Narasimhan B; Fearon WF; Lewis DB; Cooke JP; Mocarski ES; Valantine HA
    Transplantation; 2006 Aug; 82(3):398-405. PubMed ID: 16906040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection.
    Kranz B; Vester U; Wingen AM; Nadalin S; Paul A; Broelsch CE; Hoyer PF
    Pediatr Transplant; 2008 Jun; 12(4):474-8. PubMed ID: 18466436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
    Jung GO; Kim SJ; Choi GS; Moon JI; Kim JM; Sin MJ; Kim EY; Kwon CH; Joh JW; Lee SK
    Transplant Proc; 2010 Apr; 42(3):804-10. PubMed ID: 20430177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
    Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
    Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cytomegalovirus disease on early and late renal graft function.
    Boratyńska M; Banasik M; Watorek E; Patrzałek D; Szyber P; Klinger M
    Transplant Proc; 2006; 38(1):147-50. PubMed ID: 16504688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of cytomegalovirus infection and factors causing reactivation of the infection among renal transplant recipients: a single center study.
    Khameneh ZR
    Saudi J Kidney Dis Transpl; 2008 Jan; 19(1):41-5. PubMed ID: 18087121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation.
    Peterson PK; Balfour HH; Marker SC; Fryd DS; Howard RJ; Simmons RL
    Medicine (Baltimore); 1980 Jul; 59(4):283-300. PubMed ID: 6248718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.
    Erdbruegger U; Scheffner I; Mengel M; Schwarz A; Verhagen W; Haller H; Gwinner W
    Nephrol Dial Transplant; 2012 Jan; 27(1):435-43. PubMed ID: 21712490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.